BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19176031)

  • 1. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
    Li WY; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
    Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
    Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
    Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
    Jiao B; Wu CF; Liang Y; Chen HM; Xiong SM; Chen B; Shi JY; Wang YY; Wang JH; Chen Y; Li JM; Gu LJ; Tang JY; Shen ZX; Gu BW; Zhao WL; Chen Z; Chen SJ
    Leukemia; 2009 Sep; 23(9):1598-604. PubMed ID: 19458628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
    Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):866-9. PubMed ID: 19698218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
    Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
    Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Scanning of c-kit gene mutations in acute myeloid leukemias using high-resolution melting analysis].
    Yao DM; Qian J; Lin J; Chen Q; Xiao GF; Wang YL; Qian Z; Ji RB; Li Y; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):21-4. PubMed ID: 21429396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
    Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
    Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
    Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
    Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
    Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
    Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.